Surrozen says FDA cleared IND for SZN-8141 in diabetic macular edema, triggering ~$95.1M second tranche of private placement

Surrozen said the FDA cleared its IND for SZN-8141 in diabetic macular edema, a milestone that triggers the roughly $95.1 million second tranche of its private placement.

Detected & updated continuously · Source: Nebula